[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366894-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366894-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","review-of-risk-factors-and-surgical-treatment-progress-for-gallbladder-cancer","Review of risk factors and surgical treatment progress for gallbladder cancer","","Systematic review of the latest evidence on risk factors and surgical treatment strategies for gallbladder cancer, emphasizing current controversies and areas of consensus in international guidelines. Synthesizes literature from 2018–2024 to clarify genetic, environmental, and metabolic contributions, evaluate the role and limits of resection, and assess prospects for minimally invasive surgery in advanced disease. Discusses targeted therapy and immune checkpoint inhibitors, and outlines directions for clinical practice and future studies including molecular subtype-based models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/review-of-risk-factors-and-surgical-treatment-progress-for-gallbladder-cancer/366894/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/review-of-risk-factors-and-surgical-treatment-progress-for-gallbladder-cancer/366894.png","ImageObject",300,407,{"name":42,"@type":43},"LangkahRina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the review?","Question",{"text":63,"@type":64},"To systematically summarize the newest evidence on risk factors and surgical treatment for gallbladder cancer, highlighting controversies and guideline consensus, and to guide clinical practice and future research.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which risk factors are emphasized for gallbladder cancer?",{"text":68,"@type":64},"The review highlights combined genetic, environmental, and metabolic factors, including TP53 mutations, ERBB2/ERBB3 alterations, metabolic syndrome, and chronic infections.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review say about surgical treatment and its uncertainties?",{"text":72,"@type":64},"Surgical resection remains the primary curative approach, but the optimal extent of surgery is debated for different stages, including questions about hepatic resection for T1b and the safety of laparoscopic surgery for T2.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366894,1791488993,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Feng et al. Hereditas (2025) 162:240 Hereditas  \n[https://doi.org/10.1186/s41065-025-00608-z](https://doi.org/10.1186/s41065-025-00608-z)  \nREVIEW Open Access  \nReview of risk factors and surgical treatment progress for gallbladder cancer  \nJianguo Feng 1, Haihong Zhu2* and Xiaosong Wang 1  \nAbstract  \nObjective To systematically review the latest evidence on risk factors and surgical treatment for gallbladder cancer (GBC), with a focus on current controversies and consensus in international guidelines, analyze the application prospects of minimally invasive surgery in advanced GBC, and provide direction for clinical practice and future research.  \nMethods Literature on GBC risk factors, molecular mechanisms, and treatment strategies published from 2018 to 2024 was retrieved from databases including PubMed, Web of Science, and CNKI. The retrieved literature was summarized, compared, and critically analyzed.  \nResults The pathogenesis of GBC involves a combination of genetic, environmental, and metabolic factors. Beyond gallstones and polyps, mutations inTP53 and ERBB2/ERBB3 genes, metabolic syndrome (obesity, hyperglycemia, hyperlipidemia), and chronic infections (Salmonella, Helicobacter) are significant risk factors. Surgical resection remains the primary curative approach, yet the optimal extent of surgery is debated: Is hepatic resection always necessary forT1b stage? What is the oncological safety of laparoscopic surgery forT2 stage? What is the value of extended resection forT4 stage? Recently, targeted therapies (e. g., against ERBB2, NTRK) and mmune checkpoint inhibitors (anti-PD-1/PD-L1)have shown promise in advanced GBC.  \nConclusion Combating GBC requires a comprehensive strategy encompassing health education, screening of highrisk populations, precise staging, and individualized multimodal treatment. Future research should focus on building molecular subtype-based prognostic models, conducting high-level clinical studies to resolve surgical controversies, and exploring the integration of novel adjuvant therapies with traditional surgery.  \nKeywords Gallbladder cancer, Risk factors, Surgical treatment, Molecular targeted therapy, Immunotherapy  \n*Correspondence:  \nHaihong Zhu  \n[zhuhaihong1214@126.com](zhuhaihong1214@126.com)  \n1Clinical Medical College, Qinghai University, Xining, Qinghai, China 2Department of Hepatobiliary Surgery, Qinghai Provincial People’s Hospital, No. 2 Gonghe Road, Xining 810000, Qinghai, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nFeng et al. Hereditas (2025) 162:240  \nIntroduction  \nGallbladder cancer (GBC) is the most common malignant tumor of the biliary tract system, accounting for 80%−95% of biliary malignancies [1]. Its onset is insidious, making early diagnosis challenging. Most patients are diagnosed at an advanced stage, exhibiting high malignancy and extremely poor pr","cbCaiowcsucGUM2X","https://ap.wps.com/l/cbCaiowcsucGUM2X","pdf",1172057,"English","# Abstract\n# Introduction\n# Risk factors\n## Genetic factors and molecular alterations","[{\"question\":\"What is the main objective of the review?\",\"answer\":\"To systematically summarize the newest evidence on risk factors and surgical treatment for gallbladder cancer, highlighting controversies and guideline consensus, and to guide clinical practice and future research.\"},{\"question\":\"Which risk factors are emphasized for gallbladder cancer?\",\"answer\":\"The review highlights combined genetic, environmental, and metabolic factors, including TP53 mutations, ERBB2/ERBB3 alterations, metabolic syndrome, and chronic infections.\"},{\"question\":\"What does the review say about surgical treatment and its uncertainties?\",\"answer\":\"Surgical resection remains the primary curative approach, but the optimal extent of surgery is debated for different stages, including questions about hepatic resection for T1b and the safety of laparoscopic surgery for T2.\"}]","Review of risk factors and surgical treatment progress for gallbladder cancer | PDF",1790168151,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/025ba4b31259e9a3883084373eb03fdd.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6fb7f0d445a0ccd9f650a9e91a8397d.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16d9c271e5805ddde9cf78994d8d5921.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7c4c74b922c4e5d27893d8cdbd5b156.webp",980,1306]